Apabetalone, a Clinical-Stage, Selective BET Inhibitor, Opposes DUX4 Target Gene Expression in Primary Human FSHD Muscle Cells
Facioscapulohumeral dystrophy (FSHD) is a muscle disease caused by inappropriate expression of the double homeobox 4 (DUX4) gene in skeletal muscle, and its downstream activation of pro-apoptotic transcriptional programs. Inhibitors of <i>DUX4</i> expression have the potential to treat F...
Main Authors: | Christopher D. Sarsons, Dean Gilham, Laura M. Tsujikawa, Sylwia Wasiak, Li Fu, Brooke D. Rakai, Stephanie C. Stotz, Agostina Carestia, Michael Sweeney, Ewelina Kulikowski |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-09-01
|
Series: | Biomedicines |
Subjects: | |
Online Access: | https://www.mdpi.com/2227-9059/11/10/2683 |
Similar Items
-
Therapeutic Strategies Targeting DUX4 in FSHD
by: Laura Le Gall, et al.
Published: (2020-09-01) -
Expression patterns of FSHD-causing DUX4 and myogenic transcription factors PAX3 and PAX7 are spatially distinct in differentiating human stem cell cultures
by: Premi Haynes, et al.
Published: (2017-06-01) -
An in silico FSHD muscle fiber for modeling DUX4 dynamics and predicting the impact of therapy
by: Matthew V Cowley, et al.
Published: (2023-05-01) -
Molecular and Phenotypic Changes in FLExDUX4 Mice
by: Kelly Murphy, et al.
Published: (2023-06-01) -
Proximity ligation assay to detect DUX4 protein in FSHD1 muscle: a pilot study
by: Mary Lou Beermann, et al.
Published: (2022-05-01)